The Safety Rates Drug Report

Member Login
2004.Q1    2004.Q2    2004.Q3    2004.Q4    2005.Q1    2005.Q2    2005.Q3    2005.Q4    2006.Q1    2006.Q2    2006.Q3    2006.Q4    2007.Q1    2007.Q2    2007.Q3    2007.Q4    2008.Q1    2008.Q2    2008.Q3    2008.Q4    2009.Q1    2009.Q2    2009.Q3    2009.Q4    2010.Q1    2010.Q2    2010.Q3    2010.Q4    2011.Q1    2011.Q2    2011.Q3    2011.Q4    2012.Q1    2012.Q2    2012.Q3    2012.Q4    2013.Q1    2013.Q2    2013.Q3    2013.Q4    2014.Q1    2014.Q2    2014.Q3    2014.Q4    2015.Q1    2015.Q2    2015.Q3    2015.Q4    2016.Q1    2016.Q2    2016.Q3   

Drug     Injury     Quarter    

Person who experienced the adverse event (patient)

Event ID CASEID CASEVERSION I F COD EVENT DT MFR DT INIT FDA DT FDA DT REPT COD AUTH NUM MFR NUM MFR SNDR LIT REF AGE AGE COD AGE GRP GNDR COD E SUB WT WT COD REPT DT TO MFR OCCP COD REPORTER COUNTRY OCCR COUNTRY
126255261 12625526 1 I 20110318 20110405 20160805 20160805 EXP US-ROCHE-769605 ROCHE 54.42 YR M Y 112.60000 KG 20160805 MD US US

Drug(s) used by person

Event ID CASEID DRUG SEQ ROLE COD DRUGNAME PROD AI VAL VBM ROUTE DOSE VBM CUM DOSE CHR CUM DOSE UNIT DECHAL RECHAL LOT NUM EXP DT NDA NUM DOSE AMT DOSE UNIT DOSE FORM DOSE FREQ
126255261 12625526 1 PS Vismodegib VISMODEGIB 1 Oral TOTAL DOSE ADMINISTERED 3000 MG.?ON 29/MAR/2011, 19/APR/2011, 10/MAY/2011, 21/JUN/2011, 02/AUG/2011, 203388 3150 MG CAPSULE QD
126255261 12625526 2 SS Vismodegib VISMODEGIB 1 Oral 203388 3300 MG CAPSULE QD
126255261 12625526 3 SS Vismodegib VISMODEGIB 1 Oral 203388 3000 MG CAPSULE QD
126255261 12625526 4 SS Vismodegib VISMODEGIB 1 Oral 203388 2550 MG CAPSULE QD
126255261 12625526 5 SS Vismodegib VISMODEGIB 1 Oral 203388 3750 MG CAPSULE QD
126255261 12625526 6 SS ETOPOSIDE. ETOPOSIDE 1 Intravenous (not otherwise specified) DOSE FORM: 2 HOUR INFUSION ?DOSE FREQUENCY: DAYS 1-3 OF CYCLES 1-4?TOTAL DOSE RECEIVED 717 MG. 0 100 MG/M**2
126255261 12625526 7 SS CISPLATIN. CISPLATIN 1 Intravenous (not otherwise specified) DOSE FORM: 2 HOUR INFUSION?DOSE FREQUENCY: DAY 1 OF CYCLE 1-4?TOTAL DOSE RECEIVED 179.25 MG 0 75 MG/M**2
126255261 12625526 8 C ASA ASPIRIN 1 0
126255261 12625526 9 C FEXOFENADINE FEXOFENADINEFEXOFENADINE HYDROCHLORIDE 1 0
126255261 12625526 10 C JANUMET METFORMIN HYDROCHLORIDESITAGLIPTIN PHOSPHATE 1 Unknown DOSE REPORTED : 50/1000MG 0 BID
126255261 12625526 11 C LANTUS INSULIN GLARGINE 1 Unknown DOSE : 5 UNITS SQ EVERY NIGHT. 0
126255261 12625526 12 C LOMOTIL (UNITED STATES) 2 Oral DOSE FORM:TABLET? DOSE FREQUENCY: 1 TABLET TWICE A DAY AS REQUIRED 0 1 DF TABLET
126255261 12625526 13 C NASONEX MOMETASONE FUROATE 1 Unknown DOSE FREQUECY: EVERY 12 HRS IF NEEDED 0 50 UG
126255261 12625526 14 C OMEPRAZOLE. OMEPRAZOLE 1 Oral 0 20 MG BID
126255261 12625526 15 C SINGULAIR MONTELUKAST SODIUM 1 Unknown DREPORTED AS: SINGULAR 0
126255261 12625526 16 C VENTOLIN ALBUTEROL SULFATE 1 Unknown DOSE FORM: PUFF ?DOSE FREQUENCY ADDED: 1 PUFF EVERY 6 HOURS AS REQUIRED?REPORTED NAME: VENTOUN 0 90 UG

Indications of drugs used

Event ID CASEID INDI DRUG SEQ INDI PT
126255261 12625526 1 Small cell lung cancer
126255261 12625526 6 Small cell lung cancer
126255261 12625526 7 Small cell lung cancer
126255261 12625526 12 Diarrhoea

Outcome of event

Event ID CASEID OUTC COD
126255261 12625526 OT

Reactions reported

Event ID CASEID DRUG REC ACT PT
126255261 12625526 Leukocytosis
126255261 12625526 Lung infection
126255261 12625526 Neutrophil count decreased

Reporting Sources (this data is often not reported and may therefore be missing here)

no results found

Therapies reported

Event ID CASEID DSG DRUG SEQ START DT END DT DUR DUR COD
126255261 12625526 1 20110301 20130402 0
126255261 12625526 6 20110401 0
126255261 12625526 7 20110401 0